Clinical Trial Update: A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating betahistine mesilate for vertigo due to posterior circulation cerebral infarction was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vertigo

Drugs mentioned

• Betahistine Mesilate (betahistine)

Snippet

Sponsor: Eisai Inc. | Conditions: Vertigo | Phase 4 | Status: WITHDRAWN